Literature DB >> 15897993

Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii.

Abraham M Y Nomura1, Laurence N Kolonel, Kazumasa Miki, Grant N Stemmermann, Lynne R Wilkens, Marc T Goodman, Guillermo I Perez-Perez, Martin J Blaser.   

Abstract

BACKGROUND: The objective was to investigate the association of Helicobacter pylori and serum pepsinogen (PG) levels with gastric adenocarcinoma.
METHODS: Serum obtained from 299 patients at the time of cancer diagnosis and from 336 population-based control subjects was tested for PG I, PG II, and antibodies to H. pylori and to CagA.
RESULTS: Subjects with low PG I levels or low PG I/II ratios were at increased risk for cardia and noncardia gastric cancer, whereas those with H. pylori or CagA seropositivity had an elevated risk for noncardia cancer only. Subjects seropositive for either H. pylori or CagA who had low PG I levels had the highest odds ratio (OR) (9.21 [95% confidence interval {CI}, 4.95-17.13]) for noncardia cancer, compared with subjects with neither factor. Elevated risks were also found among subjects with only 1 factor (OR, 5.40 [95% CI, 2.61-11.20] for low PG I level only; OR, 4.86 [95% CI, 5.90-8.13] for H. pylori or CagA seropositivity only). This pattern persisted when PG I/II ratio replaced PG I level and when CagA seropositivity alone replaced H. pylori immunoglobulin G or CagA seropositivity.
CONCLUSIONS: The results suggest that persons with both H. pylori or CagA seropositivity and a low PG I level or PG I/II ratio are highly susceptible to development of noncardia gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897993     DOI: 10.1086/430353

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

2.  Intracellular Helicobacter pylori and gastric carcinogenesis: an "old" frontier worth revisiting.

Authors:  Andre Dubois
Journal:  Gastroenterology       Date:  2007-03       Impact factor: 22.682

Review 3.  Diet, H pylori infection and gastric cancer: evidence and controversies.

Authors:  Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

4.  The role of serum pepsinogen in the detection of gastric cancer.

Authors:  Nayoung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

5.  Equilibria of humans and our indigenous microbiota affecting asthma.

Authors:  Martin J Blaser
Journal:  Proc Am Thorac Soc       Date:  2012-05

6.  Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Authors:  Xue-Yuan Cao; Zhi-Fang Jia; Mei-Shan Jin; Dong-Hui Cao; Fei Kong; Jian Suo; Jing Jiang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis.

Authors:  Wen-Ling Mou; Meng-Yao Feng; Li-Hua Hu
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

8.  Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case-control study in Hawaii.

Authors:  Meira Epplein; Abraham M Y Nomura; Jean H Hankin; Martin J Blaser; Guillermo Perez-Perez; Grant N Stemmermann; Lynne R Wilkens; Laurence N Kolonel
Journal:  Cancer Causes Control       Date:  2008-03-28       Impact factor: 2.506

9.  Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.

Authors:  J-S Ren; F Kamangar; Y-L Qiao; P R Taylor; H Liang; S M Dawsey; B Liu; J-H Fan; C C Abnet
Journal:  Gut       Date:  2009-01-09       Impact factor: 23.059

10.  Serum pepsinogens and risk of esophageal squamous dysplasia.

Authors:  Farin Kamangar; Lena Diaw; Wen-Qiang Wei; Christian C Abnet; Guo-Qing Wang; Mark J Roth; Bing Liu; Ning Lu; Carol Giffen; You-Lin Qiao; Sanford M Dawsey
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.